Adult ADHD: What It Is and How to Assess and Treat It
DOI:
https://doi.org/10.58931/cpct.2024.2337Abstract
4.4% of the adult population, and is also prevalent in 10% of those with depressive or anxiety disorders and in 20% of those with chronic low mood. Among patients referred for treatment-resistant depression, one in three may have undiagnosed ADHD. Overall, ADHD is poorly understood, significantly undertreated, and a common reason for poor response to treatment in mood and anxiety disorders.
ADHD is not a consequence of poor parenting, indulged laziness, or excessive consumption of sugar or food dyes. It is a neurodevelopmental disorder, a “hardwiring” problem, marked by delayed maturation of the Prefrontal Cortex and allied subcortical regions that constitute the “adult” brain.
When we are young, we have limited self-control: we take what we want, say what we think, get excited, cry, and live in the moment. As our brains mature, we learn to control our behaviours, manage our emotional reactions, prioritize tasks, plan, and follow through on those plans. In individuals with ADHD, this maturation is delayed and too often remains incomplete.
References
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. doi:10.1176/ajp.2006.163.4.716
Sternat T. Abstract S2-10. Anxiety and Depression Association of America (AADA); 2016 March 31 to April 3; Philadelphia PA.
Shaw P, Malek M, Watson B, Greenstein D, de Rossi P, Sharp W. Trajectories of cerebral cortical development in childhood and adolescence and adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2013;74(8):599-606. doi:10.1016/j.biopsych.2013.04.007
Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. Jama. 2002;288(14):1740-1748. doi:10.1001/jama.288.14.1740
Di Lorenzo R, Balducci J, Poppi C, Arcolin E, Cutino A, Ferri P, et al. Children and adolescents with ADHD followed up to adulthood: a systematic review of long-term outcomes. Acta Neuropsychiatr. 2021;33(6):283-298. doi:10.1017/neu.2021.23
Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28(11):1892-1908. doi:10.1016/j.clinthera.2006.11.006
Retz W, Stieglitz RD, Corbisiero S, Retz-Junginger P, Rösler M. Emotional dysregulation in adult ADHD: what is the empirical evidence? Expert Rev Neurother. 2012;12(10):1241-1251. doi:10.1586/ern.12.109
Hirsch O, Chavanon M, Riechmann E, Christiansen H. Emotional dysregulation is a primary symptom in adult Attention-Deficit/Hyperactivity Disorder (ADHD). J Affect Disord. 2018;232:41-47. doi:10.1016/j.jad.2018.02.007
Moukhtarian TR, Reinhard I, Moran P, Ryckaert C, Skirrow C, Ebner-Priemer U, et al. Comparable emotional dynamics in women with ADHD and borderline personality disorder. Borderline Personal Disord Emot Dysregul. 2021;8(1):6. doi:10.1186/s40479-021-00144-y
Weibel S, Nicastro R, Prada P, Cole P, Rüfenacht E, Pham E, et al. Screening for attention-deficit/hyperactivity disorder in borderline personality disorder. J Affect Disord. 2018;226:85-91. doi:10.1016/j.jad.2017.09.027
Sobanski E, Brüggemann D, Alm B, Kern S, Deschner M, Schubert T, et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2007;257(7):371-377. doi:10.1007/s00406-007-0712-8
Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245-256. doi:10.1017/s0033291704002892
Arnsten AF. The Emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr. 2009;154(5):I-s43. doi:10.1016/j.jpeds.2009.01.018
Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV, et al. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res. 2020;123:21-30. doi:10.1016/j.jpsychires.2020.01.006
Zhang L, Li L, Andell P, Garcia-Argibay M, Quinn PD, D’Onofrio BM, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry. 2024;81(2):178-187. doi:10.1001/jamapsychiatry.2023.4294
Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99(2):211-216. doi:10.1016/j.pbb.2011.01.020
McCabe SE, Dickinson K, West BT, Wilens TE. Age of onset, duration, and type of medication therapy for attention-deficit/hyperactivity disorder and substance use during adolescence: a multi-cohort National study. J Am Acad Child Adolesc Psychiatry. 2016;55(6):479-486. doi:10.1016/j.jaac.2016.03.011
Brams M, Moon E, Pucci M, López FA. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. Curr Med Res Opin. 2010;26(8):1809-1825. doi:10.1185/03007995.2010.488553
Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012;21(9):477-492. doi:10.1007/s00787-012-0286-5
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Primary Care Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
